Zydus Lifesciences share price
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,135.00.
- Next results date: the board meets on 4 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,12,658 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 25.0
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 22.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 19 May 2026
- 4.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.09%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 19 May 2026
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 15,03,62852.1% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 11 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹8,017 Crup 5.67%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹990 Crdown 26.16%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 12.4%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2018, GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty. From the year to Mar 2022, the company reports a discontinued business. From the year to Mar 2023, the company's revenue for that year, ₹17,237 Cr, differs from its quarters added, ₹17,580 Cr.
| ₹ crore | Sep 2024Filed 12 Nov | Dec 2024Filed 5 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 12 Aug | Sep 2025Filed 6 Nov | Dec 2025Filed 9 Feb | Mar 2026Filed 19 May | Jun 2026Filed 11 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,865 | 7,587 | 8,017 |
| Net profit | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 | 1,341 | 990 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 17.6% | 19.5% | 19.1% | 23.1% | 20.2% | 14.9% | 17.7% | 12.4% |
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- PharmaceuticalsPharmaceuticals, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹22,412 Crup 9.09%82.6%
- Consumer productsConsumer products, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹3,954 Crup 46.57%14.6%
- Medical technologiesMedical technologies, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹782 Cr2.9%
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the years to Mar 2018, Mar 2022 and Mar 2023: days before it are of the company before the change.PE ratio and valuation history
At or below today's level on 52% of 2,480 trading days over the last 10 years.
At or below today's level on 73% of 1,975 trading days since Nov 2018.
At or below today's level on 59% of 1,975 trading days since Nov 2018.
At or below today's level on 9% of 2,480 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −1.6% | +11.4% | −11.8% | 0.1% |
| 3 years | +21.6% | +37.4% | −11.9% | 0.6% |
| 5 years | +15.3% | +19.2% | −3.8% | 0.7% |
Mutual funds holding it
207 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 120 of the 145 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 7
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 6
- AddedAdded. Funds that held more shares than at the end of the month before.
- 76
- CutCut. Funds that held fewer shares than at the end of the month before.
- 69
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 47
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 7
| Fund | |||
|---|---|---|---|
 Parag Parikh Flexi Cap FundPPFAS Mutual Fund | 1,92,62,784 | 1.54% | ₹2,238.3 Cr |
 Kotak Flexi Cap FundKotak Mahindra Mutual Fund | 1,04,11,615 | 2.28% | ₹1,209.8 Cr |
 HSBC Midcap FundHSBC Mutual Fund | 40,78,983 | 2.82% | ₹474.0 Cr |
 Bandhan Large & Mid Cap FundBandhan Mutual Fund | 29,57,548 | 1.66% | ₹343.7 Cr |
 ICICI Prudential Large Cap FundICICI Prudential Mutual Fund | 24,81,016 | 0.38% | ₹288.3 Cr |
 quant Multi Cap Fundquant Mutual Fund | 23,63,448 | 3.66% | ₹274.6 Cr |
| quant Mid Cap Fundquant Mutual Fund | 20,62,800 | 3.13% | ₹239.7 Cr |
| quant ELSS Tax Saver Fundquant Mutual Fund | 18,08,829 | 1.60% | ₹210.2 Cr |
| quant Aggressive Hybrid Fundquant Mutual Fund | 17,44,785 | 9.62% | ₹202.7 Cr |
| quant Flexi Cap Fundquant Mutual Fund | 17,31,923 | 2.75% | ₹201.2 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Zydus Lifesciences in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical IndustriesSUNPHARMA | 4,19,404 | 34.7 | 5.0 | 23.1 | +11.4% | +16.6% | 15.5% | 16.9% | 0.92% |
 Divi's LaboratoriesDIVISLAB | 2,37,594 | 81.2 | 14.2 | 59.0 | +16.3% | +26.8% | 18.4% | 20.8% | 0.34% |
 Torrent PharmaceuticalsTORNTPHARM | 1,72,094 | 78.9 | – | – | +32.9% | +8.9% | 27.3% | 11.4% | 0.84% |
 CiplaCIPLA | 1,08,093 | 32.1 | 3.1 | 20.2 | +1.8% | −37.5% | 10.3% | 11.6% | 0.97% |
 Laurus LabsLAURUSLABS | 1,06,442 | 97.4 | 20.1 | 53.5 | +22.6% | +114.9% | 22.4% | 19.8% | 0.10% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,02,624 | 31.8 | 2.7 | 20.5 | −0.9% | −43.3% | 9.0% | 6.8% | 0.65% |
 Mankind PharmaMANKIND | 91,390 | 44.6 | 5.6 | 25.4 | +13.8% | +8.2% | 13.4% | 12.8% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 90,432 | 24.4 | 2.4 | 12.5 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 24 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.00 |
| 25 Jul 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹11.00 |
| 26 Jul 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.00 |
| 28 Jul 2023 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹6.00 |
| 28 Jul 2022 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹2.50 |
| 28 Jul 2021 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.50 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
16 Oct · General Updates
Zydus Lifesciences share price by year
Each calendar year to 2025.Zydus Lifesciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 914.35 | −5.9% | 1,047.85 | 822.10 |
| 2024 | 971.70 | +41.0% | 1,300.90 | 699.15 |
| 2023 | 689.20 | +64.1% | 689.20 | 420.10 |
| 2022 | 419.95 | −13.1% | 477.25 | 330.10 |
| 2021 | 483.15 | +1.3% | 664.95 | 419.75 |
| 2020 | 476.75 | +87.5% | 489.50 | 236.90 |
| 2019 | 254.30 | −27.0% | 355.90 | 213.85 |
| 2018 | 348.45 | −19.6% | 452.00 | 337.40 |
| 2017 | 433.50 | +21.5% | 549.15 | 349.60 |
| 2016 | 356.65 | +8.9% | 424.50 | 296.55 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,138.00 | 1,143.50 | 1,118.90 | 1,129.40 | 1,126.34 | 15,03,628 | 52.1% |
| 22 Oct 2026 | 1,116.00 | 1,138.50 | 1,100.30 | 1,135.00 | 1,127.20 | 13,58,088 | 51.1% |
| 21 Oct 2026 | 1,113.70 | 1,126.90 | 1,106.00 | 1,117.30 | 1,112.91 | 7,46,594 | 50.9% |
| 19 Oct 2026 | 1,116.40 | 1,134.20 | 1,110.30 | 1,113.90 | 1,121.07 | 2,53,448 | 44.0% |
| 16 Oct 2026 | 1,140.10 | 1,146.50 | 1,123.00 | 1,123.00 | 1,130.60 | 15,98,906 | 65.1% |
| 15 Oct 2026 | 1,121.00 | 1,150.80 | 1,114.70 | 1,140.20 | 1,135.47 | 11,27,613 | 50.2% |
| 14 Oct 2026 | 1,125.00 | 1,150.90 | 1,108.00 | 1,124.70 | 1,129.64 | 23,33,866 | 54.8% |
| 13 Oct 2026 | 1,136.10 | 1,139.80 | 1,112.30 | 1,132.50 | 1,129.10 | 11,13,783 | 51.3% |
| 12 Oct 2026 | 1,117.20 | 1,139.50 | 1,107.30 | 1,134.40 | 1,124.67 | 7,89,716 | 53.7% |
| 9 Oct 2026 | 1,112.00 | 1,123.70 | 1,105.40 | 1,117.50 | 1,117.48 | 5,29,822 | 57.4% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 6 Oct 2015 | Split | 0.2000 | Each share became 5. |
| 5 Apr 2010 | Bonus | 0.6667 | Holders received 1 bonus share for every 2 held. |
About Zydus Lifesciences
Zydus Lifesciences develops, makes and sells medicines and related health products. Its portfolio covers generics, branded generics, specialty formulations, biosimilars, vaccines and active pharmaceutical ingredients (APIs), sold to patients in India, the United States and other international markets.
The business is organised into pharmaceuticals, consumer wellness, medical technology and vaccines. Pharmaceuticals is split across India, the US and international markets. Consumer wellness is run through Zydus Wellness Limited, a subsidiary. The medical technology business focuses on orthopaedics, cardiology and nephrology. APIs and alliances sit in a separate group of other businesses. In the US, Sentynl Therapeutics markets three approved rare disease therapies, and the company ranks third among generic companies there by prescriptions.
The company has 44 manufacturing facilities, 10 R&D centres and around 30,000 employees, including more than 1,500 research scientists. It manufactures in India, the US, the UK, France and Brazil. It has 75 subsidiary companies, 55 of them step-down subsidiaries, and 4 joint venture companies.
The group's roots go back to 1952, when its founder chairman, Ramanbhai B. Patel, set up an earlier laboratory business. The company belongs to the Zydus Group. Recent acquisitions include Amplitude Surgical, a French orthopaedic implant company, completed in October 2025; two biologics manufacturing facilities in California bought from Agenus, completed in January 2026; Comfort Click Limited of the UK, bought by a Zydus Wellness subsidiary; and Assertio Holdings in the US.
- Legal name
- Zydus Lifesciences Limited
- NSE symbol
- ZYDUSLIFE
- BSE code
- 532321
- ISIN
- INE010B01027
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Apr 2000
- Face value
- ₹1
- Former symbols
- CADILAHC
- CIN
- L24230GJ1995PLC025878
- Corporate identity number, the registrar of companies' code for it